Prognostic Value of BIRC5 in Lung Adenocarcinoma Lacking EGFR, KRAS, and ALK Mutations by Integrated Bioinformatics Analysis

Table 2

Cox regression analysis of risk factors associated with overall survival of TN adenocarcinoma patients.

Covariates	Univariate analysis, HR (95% CI)	value	Multivariate analysis, HR (95% CI)	value
BIRC5, high vs. low	2.184 (1.271-3.753)	0.005	2.029 (1.149-3.581)	0.015
Additional pharmaceutical therapy, yes vs. no	1.443 (0.773-2.693)	0.249
Targeted molecular therapy, yes vs. no	0.768 (0.438-1.345)	0.456
Age, per increase of 1 year	1.013 (0.985-1.041)	0.375
Gender, male vs. female	1.064 (0.635-1.781)	0.814
Recurrence/metastasis, yes vs. no	1.890 (1.127-3.171)	0.016
New tumor event after initial treatment, yes vs. no	3.936 (2.215-6.994)	<0.001
TNM staging, per increase of 1 stage	1.588 (1.231-2.048)	<0.001	1.300 (1.001-1.687)	0.049
Person neoplasm cancer status, with tumor vs. tumor-free	9.554 (4.810-18.975)	<0.001	8.539 (4.259-17.120)	<0.001
Tobacco smoking history, yes vs. no	0.739 (0.299-1.825)	0.512